Glenmark's Indore facility gets five observations from USFDA

Glenmark Pharmaceuticals (BSE: GLENMARK) disclosed that its Indore manufacturing facility concluded a USFDA inspection conducted between February 3 and February 14, 2025. The company received a Form 483 with five observations at the end of the inspection. Glenmark noted that no observation related to data integrity was reported. The company stated it would collaborate closely with the agency to address the observations and will respond to the USFDA within the stipulated timeline. The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.